NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

A new partnership between the National Institutes of Health and five major drug companies will provide a total of $6 million to several cancer centers to find ways to increase accrual to early clinical trials. The five pharmaceutical firms involved in the

A new partnership between the National Institutes of Health andfive major drug companies will provide a total of $6 million to several cancercenters to find ways to increase accrual to early clinical trials. The fivepharmaceutical firms involved in the pilot program are Aventis, Bristol-MyersSquibb, Eli Lilly and Co, GlaxoSmithKline, and Novartis. The National CancerInstitute (NCI) intends to award funds only to clinical and comprehensive cancercenters that it supports, because these institutions have the infrastructure inplace to conduct early-phase trials at the community level. Applicants willcompete for a share of approximately $3 million annually for 2 years. Half thatamount will come from the NCI and the other half from industry. The effort isnot intended to expand existing programs or systems at NCI cancer centers but toencourage novel solutions to overcome existing barriers to trial accruals andincrease the performance of the existing systems.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content